Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Conditions
Interventions
Parsaclisib
Locations
83
United States
Arizona Oncology Associates - Biltmore Cancer Center
Phoenix, Arizona, United States
Beverly Hills Cancer Center
Beverly Hills, California, United States
Synergy Hematology and Oncology Medical Associates
Los Angeles, California, United States
St. Joseph Heritage Healthcare
Santa Rosa, California, United States
American Institute of Research Corporate Office
Whittier, California, United States
Cancer Center of Central Connecticut
Southington, Connecticut, United States
Start Date
March 14, 2018
Primary Completion Date
February 26, 2021
Completion Date
June 7, 2024
Last Updated
March 14, 2025
NCT07249528
NCT04570423
NCT00131014
NCT03050268
NCT07545603
NCT07137494
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions